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The sodium glucose co-transporter-2 inhibitor dapagliflozin has been shown to decrease urinary
albumin-to-creatinine ratio (UACR). This effect, however, varies among individual patients. In
this study, we assessed the baseline characteristics and concurrent changes in other cardiovas-
cular risk markers that might be associated with UACR response to dapagliflozin. A pooled anal-
ysis of 11 phase 3 randomized, controlled clinical trials was performed. UACR change from
baseline after 24 weeks treatment with dapagliflozin 10 mg/d in 531 patients with type 2 diabe-
tes and UACR ≥30 mg/g at baseline was determined. UACR response was defined as >30%
reduction from baseline at 24 weeks, whereas UACR non-response was defined as ≤30% reduc-
tion at 24 weeks. A total of 288 (54%) patients were classified as responders and 243 (46%) as
non-responders. At 24 weeks, the UACR-adjusted mean change from baseline was −71.2% and
25.9% in responders and non-responders, respectively. Baseline characteristics were similar
between both groups. Changes in HbA1c and body weight were comparable across groups.
Responders showed a numerically larger reduction in estimated glomerular filtration rate and
systolic blood pressure versus non-responders. UACR reduction to dapagliflozin is an individual
characteristic that cannot be predicted by baseline clinical features or changes in metabolic vari-
ables. Whether UACR response would improve long-term renal and cardiovascular outcomes
remains to be determined.
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1 | INTRODUCTION
Dapagliflozin, a selective sodium glucose co-transporter-2 (SGLT2)
inhibitor, has been shown to improve glycemic control and to have
beneficial effects on other cardiovascular risk markers, including body
weight and blood pressure.1,2 Studies of SGLT2 inhibitors in patients
with type 2 diabetes with and without kidney impairment have consis-
tently reported modest reversible reductions in estimated glomerular
filtration rate (eGFR) and reductions of 30% to 40% in urinary albumin
excretion.3–6 Recent large clinical outcome trials in patients with type
2 diabetes at high cardiovascular risk have shown that SGLT2 inhibi-
tors delay the progression of kidney disease and reduce the risk of
end-stage kidney disease.3,7 Altogether, these data indicate that
SGLT2 inhibitors hold great promise as renoprotective agents for
patients with type 2 diabetes with prevalent kidney disease.
Although SGLT2 inhibitors have been shown to be effective in
lowering albuminuria and stabilizing eGFR on a population level, indi-
vidual patients may show large variations in their albuminuria
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response to these drugs, similar to what has been reported for ACE
inhibitors (ACEi) and angiotensin receptor blockers (ARBs). It has been
shown that the inter-individual variation in albuminuria response to
dapagliflozin is consistent in both the initial and subsequent exposure
to the drug,4 suggesting that this variation is based on a specific phar-
macodynamic response as opposed to merely random variation.
In order to precisely characterize the inter-individual variations in
albuminuria responses to dapagliflozin, we performed a patient-level
analysis of a large pooled phase 3 clinical trial database. To this end,
we classified patients into responders and non-responders based on
their individual change in urinary albumin : creatinine ratio (UACR)
with dapagliflozin. We then assessed baseline clinical characteristics
and concurrent changes in other cardiovascular risk markers in these
two groups.
2 | METHODS
2.1 | Study pool and patient population
This post hoc analysis was performed using pooled data from 11 phase
3, randomized, placebo-controlled clinical trials (Table S1) assessing
the effect of dapagliflozin 10 mg/d or placebo administered for
24 weeks in patients with type 2 diabetes. These studies compared
dapagliflozin 10 mg with placebo as monotherapy or in combination
with other glucose-lowering therapies, including metformin, sulphony-
lureas, thiazolidinediones, insulin, and dipeptidyl peptidase 4 inhibitors.
Two studies enrolled patients at high cardiovascular risk.8,9 Detailed
methods for individual trials have been described previously.1,8–17 All
clinical study protocols were approved by the relevant institutional
review board/ethics committee and written informed consent was
provided by the enrolled patients.
2.2 | UACR responder and non-responder definition
Patients with UACR ≥30 mg/g at baseline and assigned to dapagliflo-
zin 10 mg/d were identified and selected for the main analysis. The
patient population was then divided into UACR responders and non-
responders. UACR response was defined as >30% reduction in UACR
from baseline at week 24 of the treatment period. This threshold has
been used in prior observational studies and prospective randomized
clinical trials.18 UACR non-response was defined as ≤30% reduction in
UACR from baseline at week 24. For sensitivity analyses, UACR
response/non-response was defined as >30% reduction in UACR from
baseline at least at one time point during the 24-week treatment
period or ≤30% reduction in UACR from baseline at all time points
during the 24-week treatment period, respectively. In a second sensi-
tivity analysis, UACR response/non-response was defined as >20% or
≤20% reduction in UACR from baseline, respectively, at week 24. In a
third sensitivity analysis, UACR response/non-response was defined
as >20% reduction in UACR from baseline at least at one time point
during the 24-week treatment period or ≤20% reduction in UACR
from baseline at all time points during the 24-week treatment period,
respectively.
2.3 | Assessments and outcomes
This pooled analysis assessed changes in HbA1c, fasting plasma glucose
(FPG), eGFR, body weight, systolic blood pressure (SBP), serum uric
acid, haematocrit, and serum bicarbonate levels, as proxy for sodium-
hydrogen exchange transporter activity, from baseline to week 24 with
dapagliflozin treatment in UACR responders and non-responders. Uri-
nary albumin and creatinine levels were measured in spot urine samples,
with the ratio calculated as urine albumin (mg/L)/urine creatinine (g/L).
eGFR was calculated using the Modification of Diet in Renal Disease
equation. All biochemical assessments were conducted in central labo-
ratories in each study. The frequencies of adverse events (AEs) and seri-
ous AEs (SAEs) were also assessed in both groups.
2.4 | Statistical analyses
Descriptive statistics were used for presenting baseline characteristics
and safety data. For efficacy variables, mean change from baseline
values and 95% CI were derived using a longitudinal repeated mea-
sures mixed model with fixed terms for treatment, week, subgroup,
study, week-by-treatment interaction, treatment-by-subgroup interac-
tion, and treatment-by-week-by-subgroup interaction, as well as the
fixed covariates of baseline, baseline-by-study, and baseline-by-week
interactions. UACR values were log transformed (using the natural log).
Change in UACR was calculated as log(UACRweek24
− UACRbaseline) and
entered in the repeated measures mixed model. Results from the model
were then exponentiated back to the original scale. The Kenward-
Roger method was used. When the model did not converge, the Sat-
terthwaite approximation method was used. If this model also did not
converge, the Kenward-Roger method was used with the baseline-by-
week terms removed. Finally, if this model still did not converge,
ANCOVA was performed for each week separately. Correlation
(Pearson) analyses of baseline and changes in UACR with changes in
eGFR, serum uric acid, SBP, FPG and body weight (log-transformed
values) were also performed.
3 | RESULTS
A total of 531 patients treated with dapagliflozin 10 mg/d and who
had UACR ≥30 mg/g at baseline were available for analysis. In this
cohort, UACR was reduced at 24 weeks by 19.1% (95% CI: −27.8 to
−9.4) relative to placebo; however, there was a large variation among
individual patients in the UACR response to dapagliflozin as reflected
by the wide range in the 2.5th to 97.5th percentile values (−93.1% to
+200.9%; Figure 1).
A total of 288 patients (54.2%) showed >30% reduction in UACR
from baseline (responders), whereas 243 (45.8%) showed ≤30%
reduction (non-responders). Among non-responders, UACR levels
remained stable over time (Figure 2A). After 24 weeks, the mean
change in UACR from baseline in non-responders was 25.9% (95% CI:
17.1 to 35.4). Among responders, UACR was substantially reduced
after 4 weeks of treatment and this effect was stable and sustained
throughout the 24-week treatment period. At week 24, the average
reduction in responders was −71.2% (95% CI: −73.7 to −68.3;
Figure 2A). Among 437 patients with microalbuminuria, 136 (56.7%)
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UACR responders and 6 (3.0%) UACR non-responders regressed to
normoalbuminuria at week 24.
The baseline demographic, clinical, and biochemical characteris-
tics of UACR responders and non-responders were generally similar
(Table 1). Specifically, baseline HbA1c, eGFR, SBP and body weight
were similar between the responders and non-responders. Cardiovas-
cular disease history, as well as the use of renin-angiotensin-
aldosterone system (RAAS) inhibitor, diuretics and insulin, was similar
between both groups. A greater proportion of women were classified
as responders versus 49% of the men. When analyzed on a continu-
ous scale none of the baseline markers correlated with UACR change
(Table S2), except HbA1c and FPG, which showed significant but
weak correlations.
3.1 | Cardiovascular risk marker changes and UACR
response
FPG was decreased to a slightly larger extent in UACR responders
compared to non-responders (24-week FPG change: responders
−34.6 mg/dL [95% CI: −39.6 to −29.6] versus non-responders
−24.2 mg/dL [95% CI: −29.9 to −18.6]). HbA1c reduction was similar
between the groups (Figure 2B). Four weeks after treatment initiation,
SBP decreased to a similar degree in responders (−5.1 mm Hg,
95% CI: −6.6 to −3.7) and non-responders (−5.3 mm Hg, 95% CI:
−7.0 to −3.6; Figure 2C). However, at the end of week 24, the mean
reduction in SBP was numerically larger in the responders (−8.7 mm
Hg, 95% CI: −10.2 to −7.2) than the non-responders (−3.5 mm Hg,
95% CI: −5.3 to −1.8). Notably, eGFR change was −2.8 mL/min/1.73
m2 (95% CI: −4.0 to −1.5) in responders and −2.6 mL/min/1.73 m2
(95% CI: −4.1 to −1.0) in non-responders after 4 weeks. While the
eGFR returned to baseline values in non-responders at week 24, the ini-
tial reduction in eGFR was sustained in responders over the 24-week
treatment period (Figure 2D). Changes in body weight, haematocrit and
bicarbonate levels were similar between the two groups (Figure 2E–G).
Finally, the mean reduction in serum uric acid was larger in non-
responders than in responders at week 24 (Figure 2H).
In a continuous analysis, the change in UACR at week 4 and
week 24 in the overall population (responders and non-responders
together) was correlated with changes in other cardiovascular risk
markers (Table S3). After 4 weeks, a weak positive correlation was
observed between changes in UACR and eGFR, whereas a weak nega-
tive correlation was observed between changes in UACR and uric
acid. At week 24, changes in UACR remained positively correlated
with changes in eGFR, while the correlation of UACR with uric acid
was lost. Weak correlations were observed with SBP and FPG.
In sensitivity analyses, similar results were obtained when the
UACR response was defined as a >20% reduction from baseline at
week 24 (Figure S1), as a >30% reduction from baseline at least at
one time point during the 24-week treatment period (Figure S2), and
as a >20% reduction from baseline at least at one time point during
the 24-week treatment period (Figure S3).
3.2 | Safety
Dapagliflozin was well tolerated in both responders and non-
responders. The number of AEs, hypoglycaemic events and SAEs was
balanced between both groups. The numbers of AEs and SAEs leading
to study drug discontinuation were low (Table S4).
4 | DISCUSSION
SGLT2 inhibition with dapagliflozin has been shown to decrease albu-
minuria by approximately 35% on a population level, but with large
inter-individual variability. In this pooled analysis of multiple clinical
trials, we showed that approximately half of all patients treated with
dapagliflozin displayed a sustained reduction in UACR of >30% from
baseline, and this group experienced a mean reduction of >70% at
24 weeks of treatment. In contrast, UACR essentially did not reduce
on average in the other half of patients across the treatment period.
The reduction in UACR for individuals could not be explained by any
of the baseline characteristics analysed here, except that women
tended to be more likely to be a responder. Despite the large separa-
tion in UACR reduction between the responders and non-
responders, no differences were observed in HbA1c and body
weight. However, modest differences in eGFR and SBP were noted.
This suggests that UACR change in individuals cannot be explained
by metabolic variables and can only be partially explained by haemo-
dynamic factors.
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FIGURE 1 Distribution of albuminuria changes from baseline at
week 24. A, Histogram and B, cumulative distribution of UACR
changes at week 24; 54.2% of patients experienced >30% reduction
in UACR and 71.4% of patients experienced >0% reduction in UACR.
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The baseline biochemical and physical characteristics in
responders and non-responders were similar, indicating that none of
these variables could predict future responder status. Moreover, the
similarity in baseline UACR levels between the two groups implies
that the greater reduction in albuminuria in responders cannot be
explained by a regression to the mean phenomenon. Further studies
are required to determine if novel biomarkers measured before dapa-
gliflozin exposure could aid in predicting reduction in albuminuria with
dapagliflozin therapy.
It is improbable that the small differences observed in metabolic vari-
ables and blood pressure could explain the large separation in UACR
response between the two groups. The similarity in changes in HbA1c,
body weight and hematocrit between the two groups is in accordance
with previous studies.5,19,20 The larger and sustained reduction in eGFR in
the responder population is interesting and is most probably of haemody-
namic origin because SGLT2 inhibitors acutely decrease renal blood flow
and glomerular filtration pressure.21 The reduction in glomerular filtration
pressure is clinically manifested by an acute fall in eGFR and may, at least
in part, explain the reduction in UACR. The significant but weak correla-
tion between changes in eGFR and UACR after 4 weeks of dapagliflozin
treatment provides some support for this notion. However, it also indi-
cates that a large part of the UACR-lowering effect remained unexplained,
which has been observed in prior studies as well.5,20
The mean reduction in serum uric acid was numerically lower in
responders compared with non-responders. Urate levels depend on a
balance between uric acid generation and excretion. Uric acid is freely
filtered in the glomerulus and reabsorbed in the proximal tubule.22
The observed reduction in eGFR in the UACR responder group may
have decreased uric acid filtration, resulting in less pronounced lower-
ing of serum uric acid in the responders.
The studies used to generate the data described in this paper were
not designed to characterize individual responses of albuminuria to
dapagliflozin. Hence, the results from this post hoc analysis can only be
interpreted as hypothesis-generating. A large randomized cross-over
study where patients are exposed to placebo and dapagliflozin during
various consecutive treatment periods would be the optimal design to
assess individual treatment responses. Additionally, UACR was mea-
sured in single spot urine samples in most studies. The measurement of
UACR in spot urine samples is subject to a large day-to-day variability
causing random noise that may weaken the reported associations.
Future studies with more frequent urine sampling using first morning
void or 24-hour urine samples, which have been shown to be less vari-
able over time in an individual, should be used to gain further mechanis-
tic understanding of the differential response in UACR. For example, a
better understanding of the alterations in intra-glomerular pressure and
other determinants of glomerular albumin permeability, such as the gly-
cocalyx, would be needed to better assess how these factors determine
individual UACR responses to SGLT2 inhibition.
In conclusion, the albuminuria response to dapagliflozin is an indi-
vidual characteristic that is only partly associated with changes in
blood pressure and eGFR; however, it is not readily explained by rou-
tinely available clinical laboratory variables or changes in metabolic
variables, but is partly associated with changes in eGFR and SBP. Fur-
ther studies are required to determine whether UACR responders to
SGLT2 inhibitors show improved renal and cardiovascular outcomes
compared with non-responders.
TABLE 1 Baseline characteristics of patients who received
dapagliflozin stratified by UACR response
Baseline characteristics
Responders
(n = 288)
Non-responders
(n = 243)
Age, y 59.3 (10.3) 60.0 (8.8)
Women 121 (42.0) 68 (28.0)
Men 167 (58.0) 175 (72.0)
Race
White 244 (84.7) 202 (83.1)
Black 12 (4.2) 9 (3.7)
Asian 28 (9.7) 22 (9.1)
Other 4 (1.4) 10 (4.1)
Duration of type
2 diabetes, y
10.6 (8.9) 10.6 (8.2)
UACR, mg/g 86.0 (48.5–165.5) 69.0 (42.0–162.0)
≥30 to <300 240 197
≥300 44 46
Body weight, kg 91.5 (19.6) 93.9 (22.7)
sUA, mg/dL 5.60 (1.5) 5.88 (1.7)
HbA1c, % 8.38 (0.9) 8.15 (0.9)
HbA1c, mmol/mol 68 66
Haematocrit, % 42.1 (4.2) 42.6 (4.0)
Serum bicarbonate,
mEq/L
25.3 (2.8) 25.8 (3.0)
SBP, mm Hg 136.8 (15.3) 136.6 (14.8)
DBP, mm Hg 79.6 (9.9) 78.7 (8.8)
Pulse pressure, mm Hg 57.2 (13.8) 57.9 (13.1)
eGFR, mL/min/1.73 m2 80.3 (19.2) 80.7 (21.1)
≥30 to <45 7 (2.4) 7 (2.9)
≥45 to <60 26 (9.0) 36 (14.8)
≥60 to <90 176 (61.1) 118 (48.6)
≥90 79 (27.4) 82 (33.7)
Baseline medications
Loop diuretics 35 (12.2) 42 (17.3)
Thiazide diuretics 31 (10.8) 18 (7.4)
ACEi/ARB 226 (78.5) 190 (78.2)
Insulin 125 (43.4) 103 (42.4)
SU 82 (28.5) 81 (33.3)
TZD 72 (25.0) 55 (22.6)
DPP4 inhibitors 27 (9.4) 18 (7.4)
Disease history
CVD and/or HF 160 (55.6) 158 (65.0)
Hypertension 237 (82.3) 208 (85.6)
Dyslipidaemia 195 (67.7) 190 (78.2)
PVD/PAD 42 (14.6) 47 (19.3)
Abbreviations: ACEi, ACE inhibitor; ARB, angiotensin receptor blocker;
CVD, cardiovascular disease; DBP, diastolic blood pressure; DPP4, dipepti-
dyl peptidase 4; eGFR, estimated glomerular filtration rate; HF, heart fail-
ure; PAD, peripheral arterial disease; PVD, peripheral vascular disease;
SBP, systolic blood pressure; SD, standard deviation; SU, sulphonylurea;
sUA, serum uric acid; T2D, type 2 diabetes; UACR, urine albumin : creati-
nine ratio. Data are presented as mean (SD) or number (%). UACR values
represent median (25th, 75th percentile) values in patients with UACR
≥30 mg/g at baseline.
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FIGURE 2 Changes in renal and cardiovascular risk markers over time in UACR responders and non-responders. A, UACR; B, HbA1c; C, SBP; D,
eGFR; E, body weight; F, haematocrit; G, bicarbonate levels; H, sUA. Abbreviations: Adj., adjusted; eGFR, estimated glomerular filtration rate;
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